Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Troels K H Scheel Clear advanced filters

  • Hepatitis C virus utilizes flavin adenine dinucleotide as a non-canonical initiating nucleotide for the viral RNA polymerase, resulting in 5′ capping of viral RNA, which provides protection against the host innate immune response.

    • Anna V. Sherwood
    • Lizandro R. Rivera-Rangel
    • Jeppe Vinther
    Research
    Nature
    Volume: 619, P: 811-818

  • RNA-Binding Proteins (RBPs) are critical regulators of RNA biology. Here, the authors describe the Brain-pCLAP methodology, uncover the RBP atlas of the mouse brain and demonstrate the differential binding of the splicing factor RBM5 to Huntington’s disease relevant transcripts in R6/2 mice.

    • Meeli Mullari
    • Nicolas Fossat
    • Michael L. Nielsen
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-20

  • microRNAs (miRNAs) act as sequence-specific guides for Argonaute (AGO) proteins. By using a modified AGO HITS-CLIP strategy that enriches miRNAs ligated to their endogenous mRNA targets, here the authors show that miRNA 3' end pairing is a general determinant of AGO binding specificity.

    • Michael J. Moore
    • Troels K. H. Scheel
    • Robert B. Darnell
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-17

  • A new wave of antivirals to fight hepatitis C infection has helped patients achieve a good quality of life, but drug resistance, side effects and a lack of pan-viral genotype coverage still remains a problem. This Review discusses current clinical studies and potential targets of the virus life cycle to tackle these issues and puts forward a paradigm to develop second-generation effective antivirals and drug combinations for achieving the ideal regimen of an all-oral, interferon-free therapeutic cocktail.

    • Troels K H Scheel
    • Charles M Rice
    Reviews
    Nature Medicine
    Volume: 19, P: 837-849